Two-step legislative approach to Prescription Drug Affordability Board – proposed modifications to OR S 844

**In 2021**

Establish a PDAB and stakeholder council per existing bill language. Funding per existing bill language

**In 2022:**

Per existing bill language Report to the legislature on the role of each part of the full prescription drug supply chain and prescription drug financing chain – insurers, their contract PBMs, and patients -- in the cost of and access to prescription drugs for insured and uninsured Oregonians.[[1]](#endnote-1)

**In 2022-2023**

Per existing bill language, PDAB would identify drugs using current monetary thresholds for the different types of drugs in S 844.

Per existing 844, determine if any of those drugs create an affordability challenge for OR healthcare system and patients. If yes, determine if a cost review is warranted. If yes, conduct a cost review to determine if the drug does indeed create an affordability challenge.

If the drug is determined to create financial stress/drug cost is limiting access then, produce an analysis/report for that drug which:

1. Recommends an upper payment limit for the drug that would, if applied, affect all financial transactions around that drug in the state and specify the methodology used to arrive at that recommended UPL, detailing how the UPL would not undermine the viability of any part of the supply chain **AND**
2. Recommends any other approach that would, if applied, make that same drug affordable to any resident who required that drug and which would not raise healthcare premiums/coverage costs or undermine the viability of any part of the supply chain.

**In 2023**

Request from the legislature the authorities needed by the PDAB to make drugs affordable for any Oregonian, based on the analysis of items 1 and 2 above.

1. 340B may or may not be something OCAP wants to consider for this report. It came up in CO [↑](#endnote-ref-1)